Physician profile
Jalil E Ahari
NPI 1205010808
$1,239.63
in general payments reported to CMS, 2019-2025
15 companies · $742 in 2025
The $742 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $163 · 2021: $48.70 · 2022: $15.39 · 2023: $119 · 2024: $152 · 2025: $742.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $923 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $922.72 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $363.71 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $255.19 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Zoll Respicardia, INC. | $127.66 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $96.85 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $85.58 | 2025 | Glassia |
| Glaxosmithkline, LLC. | $46.83 | 2022-2025 | Nucala |
| Harmony Biosciences LLC | $43.20 | 2025 | |
| Fisher & Paykel Healthcare INC | $35.49 | 2025 | Fisher & Paykel Healthcare |
| Lilly USA, LLC | $31.61 | 2025 | Zepbound |
| Axsome Therapeutics, INC. | $30.02 | 2024 | Sunosi |
| Genzyme Corporation | $29.94 | 2021 | |
| Avadel Cns Pharmaceuticals, LLC | $29.89 | 2025 | Lumryz |
| Actelion Pharmaceuticals US, INC. | $23.09 | 2019 | |
| Amgen INC. | $21.81 | 2023 | Tezspire |
| United Therapeutics Corporation | $18.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jalil Ahari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.